ReviewEye (London, England)2019
Retinoblastoma in Asia.
Review in Eye (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Quality of life among people with eye cancer: a systematic review from 2012 to 2022.Health and quality of life outcomes · 2024Pooled it
- 망막모세포종에 대한 일차 및 대안 경로를 통한 동맥 내 화학요법의 안구 보존 결과: 인도네시아 단일 기관 경험.Journal of the Korean Society of Radiology · 2026Article
- Global research trends on intra-arterial chemotherapy for retinoblastoma: A bibliometric and visualized study.Medicine · 2026Article
- Patient-derived spheroid culture: A promising in vitro model for drug screening in retinoblastoma.Medical oncology (Northwood, London, England) · 2026Article
- Efficacy and safety analysis of autologous hematopoietic stem cell transplantation for extraocular retinoblastoma.Frontiers in pediatrics · 2026Article
- Retinoblastoma survival trend: a 30-year analysis from a referral single center in Iran.International journal of retina and vitreous · 2025Article
- A Comprehensive Review of the Epidemiology, Pathophysiology, Risk Factors, and Treatment Strategies for Retinoblastoma.Diseases (Basel, Switzerland) · 2025Review
- Article
- Tumor heterogeneity in retinoblastoma: a literature review.Cancer metastasis reviews · 2025Review
- Investigation of GD2 synthase as a potential marker for retinoblastoma poor prognosis.Molecular biology reports · 2025Article
- Article
- The niosomal nelarabine as a promising nano combination for retinoblastoma treatment: anAnnals of medicine and surgery (2012) · 2025Article
- Urbanization Inequalities on the Incidence of Intraocular Cancers in Iran: An 11-Year Nationwide Retrospective Ecological Study.Journal of ophthalmic & vision research · 2025Article
- Advances in Extracellular-Vesicles-Based Diagnostic and Therapeutic Approaches for Ocular Diseases.ACS nano · 2024Review
- Retinoblastoma patients treated in Sri Lanka from 2014 to 2020: epidemiology, clinical status and correlates of lag time in seeking tertiary care services.BMC ophthalmology · 2024Article
- The Impact of Tumor Laterality (Unilateral vs. Bilateral) on Presentation and Management Outcome in Patients with Retinoblastoma.Journal of clinical medicine · 2024Article
- Identification of dysregulation of sphingolipids in retinoblastoma using liquid chromatography-mass spectrometry.Experimental eye research · 2024Article
- Advancements in Retinoblastoma Treatment: Unraveling the Potential of Intravitreal Chemotherapy.Cureus · 2024Review
- Polydopamine-Based Targeted Nanosystem for Chemo/Photothermal Therapy of Retinoblastoma in a Mouse Orthotopic Model.International journal of nanomedicine · 2024Article
- Enhanced anti-tumor activity of transferrin/folate dual-targeting magnetic nanoparticles using chemo-thermo therapy on retinoblastoma cancer cells Y79.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asia-Pacific region bears a significant global burden of retinoblastoma (RB), therefore understanding RB in Asia-Pacific region is important. Based on the year 2013 population estimates, 43% (3452 of 8099 children) of the global burden of RB lives in 6 countries of Asia-Pacific region: 1486 children in India, 1103 children in China, 277 children in Indonesia, 260 children in Pakistan, 184 children in Bangladesh, 142 children in Philippines. There exists a wide disparity, technological and socio-economical, within countries in this region resulting in a varied pattern of clinical presentation and survival varies. Challenges in developing nations are not just technological, but also social. Opportunities emerge for research to study and understand the socio-economical aspects of the disease to develop interventions that are relevant culturally and feasible economically. Possible steps include disease education and counselling, universal screening, highly subsidized/free of cost treatment for low socioeconomic strata, raising funds through the government and non-governmental organizations, sensitization and training of man-power in screening, diagnosis and treatment, and developing new specialized centers with tele-ophthalmology services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.